https://www.macrotrends.net/stocks/charts/SABS/sab-biotherapeutics/market-cap
SAB Biotherapeutics market cap history and chart from 2021 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the...
market capsabbiotherapeuticsmacrotrends
https://www.benzinga.com/news/earnings/22/03/26397536/bolt-biotherapeuticss-return-on-capital-employed-overview
Bolt Biotherapeutics (NASDAQ:BOLT) brought in sales totaling $508.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased...
boltbiotherapeuticsreturncapitalemployed
https://www.globenewswire.com/fr/news-release/2025/09/30/3158558/0/en/Barinthus-Biotherapeutics-to-Combine-with-Clywedog-Therapeutics-to-Target-Metabolic-and-Autoimmune-Diseases.html
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being...
barinthus biotherapeuticscombineclywedog
https://www.webull.com/quote/otcpk-cldww
Webull offers Calidi Biotherapeutics (CLDWW) historical stock prices, in-depth market analysis, OTCPK: CLDWW real-time stock quote data, in-depth charts.
stock quotesbiotherapeuticswebull
https://www.pharmaceutical-technology.com/data-insights/lifileucel-iovance-biotherapeutics-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-259260&utm_campaign=recommended-articles-pi
Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.
iovance biotherapeuticslifileucelrecurrentheadneck
https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-lymphoma-likelihood-of-approval/
Autologous SUPLEXA is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Lymphoma.
autologousbiotherapeuticslymphomalikelihoodapproval
https://theorg.com/org/genetix-biotherapeutics/org-chart/melissa-mankey
Melissa Mankey is a highly experienced quality assurance professional with a career spanning multiple organizations in the biotechnology and pharmaceutical...
quality assurancedrug productmelissamankeysenior
https://www.cancerresearchhorizons.com/news-and-events/our-news/aleta-biotherapeutics-and-cancer-research-uk-announce-promising-phase-1/2
Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development presented the trial results at the American Society of Hematology Annual Meeting...
cancer research ukaletabiotherapeuticsannouncepromising
https://www.genetixbiotx.com/
bluebird bio has rebranded as Genetix Biotherapeutics, returning to our foundational roots and renewing our commitment to delivering transformative genetic...
genetixbiotherapeutics
https://finviz.com/news/92002/applied-dna-sharpens-strategic-focus-on-synthetic-dna-manufacturing-for-biotherapeutics-applications-consolidates-operations-behind-linearx
Stock screener for investors and traders, financial visualizations.
strategic focusapplieddnasyntheticmanufacturing
https://www.pharmaceutical-technology.com/data-insights/iovance-biotherapeutics-files-patent-for-coordinating-manufacturing-of-expanded-t-cells-for-cancer-treatment/
Discover a streamlined method for manufacturing expanded T cells for cancer treatment. This patent outlines a comprehensive process, utilizing computing...
iovance biotherapeuticsincpatentfiledcoordinating
https://www.etoro.com/it/markets/atra
Scopri prezzi azionari, quotazioni, news e previsioni degli analisti su Atara Biotherapeutics Inc in tempo reale su eToro. Analisi dei trend di mercato e delle...
atara biotherapeuticsle notizieilprezzodelle
https://www.pharmaceutical-technology.com/data-insights/oberotatug-ravtansine-oxford-biotherapeutics-gastric-cancer-likelihood-of-approval/
Oberotatug ravtansine is under clinical development by Oxford BioTherapeutics and currently in Phase I for Gastric Cancer.
gastric cancerravtansineoxfordbiotherapeuticslikelihood
https://www.uu.nl/nieuws/gestur-vidarsson-benoemd-tot-hoogleraar-of-immunoglobulin-biotherapeutics
Immunoloog Gestur Vidarsson onderzoekt hoe een suiker in antilichamen afweerreacties doet afnemen. De suiker eruit halen, kan een immuunreactie sterker maken.
vidarssontotimmunoglobulinbiotherapeuticsnieuws
https://www.pharmaceutical-technology.com/data-insights/ql-335-qlsf-biotherapeutics-colorectal-cancer-likelihood-of-approval/
QL-335 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Colorectal Cancer.
colorectal cancerqlbiotherapeuticslikelihood
https://www.macrotrends.net/stocks/charts/ARQT/arcutis-biotherapeutics/dividend-yield-history
Historical dividend payout and yield for Arcutis Biotherapeutics (ARQT) since 1971. The current TTM dividend payout for Arcutis Biotherapeutics (ARQT) as of...
dividend historybiotherapeuticsyearmacrotrends
https://capital.com/nl-nl/markets/shares/bolt-biotherapeutics-inc-aandeelprijs-1
Get Bolt Biotherapeutics, Inc. (BOLT) real-time share value, investment, rating and financial market information from Capital. Friendly Platforms & Trading...
boltbiotherapeuticsinckoersen
https://www.pharmaceutical-technology.com/news/aro-biotherapeutics-pompe-disease/
Aro Biotherapeutics has raised $41.5m in a Series B financing round to advance the development of ABX1100 for Pompe disease.
pompe diseasearobiotherapeuticsraisesfunds
https://builtin.com/job/gmp-auditor-qa-compliance/7504788
Artiva Biotherapeutics is hiring for a GMP Auditor, QA Compliance in San Diego, CA, USA. Find more details about the job and how to apply at Built In.
gmp auditorqacompliancebiotherapeuticsbuilt
https://www.macrotrends.net/stocks/charts/IOVA/iovance-biotherapeutics/profit-margins
Current and historical gross margin, operating margin and net profit margin for Iovance Biotherapeutics (IOVA) over the last 10 years. Profit margin can be...
iovance biotherapeuticsprofit marginmacrotrends
https://theorg.com/org/genetix-biotherapeutics/org-chart/anjulika-chawla
Anjulika Chawla is currently the VP, Head of Clinical Research and Development at Genetix Biotherapeutics, with experience spanning several prestigious...
clinical researchchawlavpdevelopmentgenetix
https://www.globenewswire.com/fr/news-release/2025/09/30/3158744/0/en/Barinthus-Biotherapeutics-to-Combine-with-Clywedog-Therapeutics-to-Target-Metabolic-and-Autoimmune-Diseases.html
GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The combined company, Clywedog Therapeutics, will bring a portfolio that includes...
barinthus biotherapeuticscombineclywedog
https://www.statnews.com/2025/12/15/biotech-news-sobi-next-gen-gout-drug-acquisition/
Dec 15, 2025 - Biotech news today includes: Sobi betting big on a next-gen gout drug, brain-targeted gene therapy's sobering reckoning, and more.
biotherapeuticssobigskreadoutnewsletter
https://www.pharmaceutical-technology.com/data-insights/ata-3219-atara-biotherapeutics-net-present-value/
ATA-3219 is a gene-modified cell therapy commercialized by Atara Biotherapeutics, with a leading Phase I program in Diffuse Large B-Cell Lymphoma;Mantle Cell...
net present valuerisk adjustedcurrentvaluation
https://www.webull.com/quote/nasdaq-bolt
Webull offers Bolt Biotherapeutics, Inc. (BOLT) historical stock prices, in-depth market analysis, NASDAQ: BOLT real-time stock quote data, in-depth charts.
stock quotesboltbiotherapeuticsincwebull
https://www.pharmaceutical-technology.com/data-insights/csb-001-claris-biotherapeutics-keratitis-likelihood-of-approval/
CSB-001 is under clinical development by Claris Biotherapeutics and currently in Phase II for Keratitis.
csbclarisbiotherapeuticskeratitislikelihood
https://www.hl.co.uk/shares/shares-search-results/p/protalix-biotherapeutics-inc-usd0.0001/company-information
Company information for Protalix Biotherapeutics Inc (PLX) including general stock details, key personnel and important dates for your diary.
protalix biotherapeuticscompany informationincplx
https://www.macrotrends.net/stocks/charts/SNSE/sensei-biotherapeutics/total-liabilities
Sensei Biotherapeutics total liabilities from 2020 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
total liabilitiessenseibiotherapeuticssnsemacrotrends
https://www.pharmaceutical-technology.com/data-insights/viper-101-vittoria-biotherapeutics-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/
VIPER-101 is under clinical development by ViTToria Biotherapeutics and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic...
vipervittoriabiotherapeuticscelllymphoma
https://www.finanznachrichten.de/nachrichten-2025-06/65558347-original-research-sernova-biotherapeutics-inc-von-first-berlin-equity-research-gmbh-buy-016.htm
Original-Research: Sernova Biotherapeutics Inc - from First Berlin Equity Research GmbH 02.06.2025 / 13:39 CET/CEST Dissemination of a Research, transmitted by...
original researchbiotherapeuticsincvonfirst
https://capital.com/nl-nl/markets/shares/iovance-biotherapeutics-aandeelprijs-1
Get Iovance Biotherapeutics (IOVA) real-time share value, investment, rating and financial market information from Capital. Friendly Platforms & Trading today.
iovance biotherapeuticskoersengrafiekhandel
https://www.benzinga.com/quote/SNSE/news
Get the latest news on Sensei Biotherapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SNSE performance
stock newslatestsenseibiotherapeuticsnasdaq
https://investorplace.com/earning-results/2024/03/bolt-stock-earnings-bolt-biotherapeutics-for-q4-of-2023/?utm_source=financialcontent&utm_medium=quotes
BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
boltstockearningsbiotherapeuticsbeats
https://www.pharmaceutical-technology.com/data-insights/irl-201104-revolo-biotherapeutics-eosinophilic-esophagitis-likelihood-of-approval/
IRL-201104 is under clinical development by Revolo Biotherapeutics and currently in Phase II for Eosinophilic Esophagitis.
eosinophilic esophagitisirlrevolobiotherapeuticslikelihood
https://www.biospace.com/press-releases/fore-biotherapeutics-to-present-two-plixorafenib-abstracts-at-the-american-association-for-cancer-research-annual-meeting-2025
forebiotherapeuticspresenttwoabstracts
https://edubirdie.com/docs/university-of-wolverhampton/4py019-pharmacy/70533-peptides-and-proteins
Biotherapeutics: Biopharmaceuticals are pharmaceuticals inherently biological in nature due to their method of manufacture; specifically those using... Read...
deep divebiotherapeuticsbiologicalpharmaceuticalsedubirdie
https://www.pharmaceutical-technology.com/data-insights/jk-07-salubris-biotherapeutics-systolic-heart-failure-likelihood-of-approval/
JK-07 is under clinical development by Salubris Biotherapeutics and currently in Phase II for Systolic Heart Failure.
systolic heart failurejksalubrisbiotherapeuticslikelihood
https://www.pharmaceutical-technology.com/data-insights/atara-biotherapeutics-gets-grant-for-treatment-of-solid-malignant-tumors-using-antigen-specific-t-cells/
Discover how Atara Biotherapeutics Inc's patent revolutionizes cancer treatment with antigen-specific T cells for solid tumors. Learn about managing tumor...
meta titleatara biotherapeuticsincpatenttreatment
https://www.businesswire.com/news/home/20250430350619/en/FORE-Biotherapeutics-to-Present-Plixorafenib-Abstract-at-the-2025-American-Society-of-Clinical-Oncology-Annual-Meeting
FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced ...
forebiotherapeuticspresentabstractamerican
https://www.biospace.com/iovance-biotherapeutics-inc-announces-public-offering-of-common-stock
Iovance intends to use the proceeds from this offering to fund its ongoing clinical trials for its current product candidates, including its ongoing Phase 2...
iovance biotherapeuticspublic offeringcommon stockannouncesjan
https://listlabs.com/
List Labs is a Microbiome CDMO that also manufactures research reagents and bacterial toxins and provides cGMP manufacturing for drug development. Read more.
microbialcdmofocusedlivebiotherapeutics
https://www.pharmaceutical-technology.com/data-insights/taa-05-persongen-biotherapeutics-suzhou-refractory-acute-myeloid-leukemia-likelihood-of-approval/
TAA-05 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Refractory Acute Myeloid Leukemia.
taabiotherapeuticssuzhourefractoryacute
https://theorg.com/org/genetix-biotherapeutics/org-chart/paul-osullivan
Paul O'Sullivan is currently the Director of Quality Assurance at bluebird bio, where Paul oversees a team that supports manufacturing and release of products.
quality assurancepaulsullivandirectorgenetix
https://www.finanznachrichten.de/nachrichten-2025-07/65864960-sernova-biotherapeutics-inc-sernova-biotherapeutics-announces-collaboration-with-eledon-pharmaceuticals-to-advance-a-potential-functional-cure-for-399.htm
LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a...
biotherapeuticsincannouncescollaboration
https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/
TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Non-Small Cell Lung Cancer.
small celltiltbiotherapeuticsnonlung
https://www.biospace.com/alethia-biotherapeutics-inc-announces-in-licensing-of-a-peptide-for-imaging-of-solid-tumors-in-vivo-and-positive-pre-clinical-results-of-ab-16b5-in
alethiabiotherapeuticsincannounceslicensing
https://www.hl.co.uk/shares/shares-search-results/i/iovance-biotherapeutics-inc-usd0.000041666/share-charts
The latest Iovance Biotherapeutics Inc (IOVA) USD0.000041666 share price (IOVA). View recent trades and share price information for Iovance Biotherapeutics Inc...
iovance biotherapeuticsshare priceinc
https://www.benzinga.com/news/23/07/33168096/why-iovance-biotherapeutics-iova-shares-are-exploding-higher
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading higher by 14.3% to $8.28 Monday morning after the company announced regulatory, clinical updates...
iovance biotherapeuticssharesexplodinghigher
https://www.pharmaceutical-technology.com/data-insights/bolt-biotherapeutics-files-patent-for-immunoconjugates-for-cancer-treatment-using-elastase-substrate-peptide-linker/
Discover a groundbreaking immunoconjugate patent by Bolt Biotherapeutics Inc. that revolutionizes cancer treatment. Learn about the cell-binding agent and...
cancer treatmentboltbiotherapeuticsincimmunoconjugates
https://www.benzinga.com/news/earnings/23/11/35705816/crude-oil-rises-over-1-tapestry-posts-upbeat-earnings
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 50 points on Thursday. The Dow traded up 0.01% to 34,114.64...
crude oilrisestapestrypostsupbeat
https://theorg.com/org/genetix-biotherapeutics/org-chart/carly-duvall
Carly Duvall is an experienced marketing professional currently serving as the Director of Marketing at bluebird bio, focusing on beta-thalassemia and sickle...
commercial operationscarlyduvalldirectorgenetix
https://www.pharmaceutical-technology.com/news/cancer-research-research-hub/
Cancer Research UK has launched a global centre of excellence in London to facilitate research on biotherapeutics as a treatment option for cancer.
cancer research uknew hublaunchesbiotherapeutics
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/iovance-biotherapeutics-inc-nasdaqiova-just-reported-earning
There's been a major selloff in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) shares in the week since it released its...
iovance biotherapeuticsincnasdaqreportedearnings
https://www.globenewswire.com/news-release/2026/01/16/3220580/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html
SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (
iovance biotherapeuticsreportsinducementgrants
https://www.pharmaceutical-technology.com/data-insights/northwest-biotherapeutics-gets-grant-for-method-for-deriving-immature-dendritic-cells-from-monocytic-precursors/
Generate immature dendritic cells for immunotherapy with Northwest Biotherapeutics Inc's patented method using GM-CSF alone. Learn more about this innovative...
northwest biotherapeuticspatent filingdendritic cellsincmethod
https://www.radboudumc.nl/en/partners/spin-off-companies/simmunext-biotherapeutics-bv
Looking for information about simmunext Biotherapeutics BV? Read more about this simmunext Biotherapeutics BV at Radboudumc
biotherapeuticsbvradboudumc
https://www.investorbrandnetwork.com/clients/calidi-biotherapeutics-inc/
Jul 8, 2025 - Investment Considerations Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of systemic...
nyse americanbiotherapeuticsinccldiibn
https://www.insidermonkey.com/blog/should-you-buy-atara-biotherapeutics-inc-atra-392623/
Is Atara Biotherapeutics Inc (NASDAQ:ATRA) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of...
atara biotherapeuticsbuyincatrainsider
https://www.macrotrends.net/stocks/charts/SABS/sab-biotherapeutics/debt-equity-ratio
Current and historical debt to equity ratio values for SAB Biotherapeutics (SABS) over the last 10 years. The debt/equity ratio can be defined as a measure of...
equity ratiosabbiotherapeuticsdebtmacrotrends
https://www.pharmaceutical-technology.com/data-insights/st-266-noveome-biotherapeutics-necrotizing-enterocolitis-likelihood-of-approval/
ST-266 is under clinical development by Noveome Biotherapeutics and currently in Phase II for Necrotizing Enterocolitis.
necrotizing enterocolitisstbiotherapeuticslikelihood
https://www.mayo.edu/research/centers-programs/center-regenerative-biotherapeutics/about/glossary
Find common terms and definitions used in the Mayo Clinic Center for Regenerative Biotherapeutics, including at our biomanufacturing sites and in our quality...
mayo clinic researchglossarycenterregenerativebiotherapeutics
https://www.technologynetworks.com/immunology/news/alethia-biotherapeutics-announces-the-nomination-of-a-new-board-member-to-its-board-of-directors-185873
Mr. Christopher J. Morl, an experienced biotech executive who brings to Alethia significant experience in business and corporate development has joined Board...
new boardalethiabiotherapeuticsannouncesnomination
https://www.businesswire.com/news/home/20251112949094/en/Atara-Biotherapeutics-Announces-Third-Quarter-Financial-Results-and-Operational-Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to dev...
atara biotherapeuticsthird quarterfinancial resultsannouncesoperational
https://www.biospace.com/linkedup-bioscience-and-tianti-biotherapeutics-successfully-resolve-legal-dispute-with-adimab
LinkedUp Bioscience and TianTi Biotherapeutics are pleased to announce the resolution of the lawsuit brought by Adimab, LLC, and related parties.
legal disputelinkedupbiosciencetiantibiotherapeutics
https://www.macrotrends.net/stocks/charts/BRNS/barinthus-biotherapeutics/total-share-holder-equity
Barinthus Biotherapeutics share holder equity from 2020 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
barinthus biotherapeuticsshare holderequitybrnsmacrotrends
https://www.nasdaq.com/market-activity/stocks/iova/insider-activity
Find the latest information on Iovance Biotherapeutics, Inc. Common Stock (IOVA) insider activity and insider shares traded to make sound investments with...
iovance biotherapeuticscommon stockincinsideractivity
https://www.bdc.ca/en/bdc-capital/venture-capital/portfolio/alethia-biotherapeutics
Alethia is developing innovative therapeutic approaches in areas of unmet medical needs, capitalizing on its capacity to identify and validate disease-specific...
portfolio companyalethiabiotherapeuticsincbdc
https://www.biospace.com/first-treatment-for-sab-biotherapeutics-mers-drug-appears-safe-in-nih-phase-i-clinical-trial
Results of the study were published today in The Lancet Infectious Diseases.
firsttreatmentsabbiotherapeuticsmers
https://www.notebookcheck.net/Roche-teams-with-Oxford-BioTherapeutics-to-develop-antibody-cancer-treatments.982655.0.html
Oxford BioTherapeutics partners with Roche in a deal worth potentially over $1 billion to develop novel cancer antibody treatments.
cancer treatmentsrocheteamsoxfordbiotherapeutics
https://www.benzinga.com/general/biotech/21/06/21761254/iovance-biotherapeutics-til-therapy-achieves-orr-of-21-4-in-pre-treated-lung-cancer-patients
iovance biotherapeuticstiltherapyorr
https://www.waters.com/nextgen/in/en/library/application-notes/2010/mass-accuracy-for-biotherapeutics-in-the-benchtop-xevo-g2-qtof-with-quantof-technology.html
Every aspect of the Xevo G2 QTof applies the design ethic of Engineered Simplicity to efficiently obtain the right results every time. Equipped with QuanTof...
mass accuracybiotherapeuticsbenchtopxevoqtof